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Abstract 11 
Oral vaccines are highly desirable due to simple logistics, mass vaccination potential and for 12 
mucosal immunity. Subunit vaccines are preferred due to high safety, but are inherently 13 
difficult to deliver orally, thus providing motivation for the use of advanced oral delivery 14 
systems. Polymeric devices in micrometer size (microcontainers) were tested here for this 15 
purpose. Microcontainers were loaded with a vaccine consisting of spray dried cubosomes 16 
with OVA and Quil-A, and coated with a pH-sensitive lid for oral delivery to C57Bl/6 mice. 17 
The microcontainers were explored in vitro and in vivo for their potential as oral vaccine 18 
delivery system in an oral prime-boost setting and as an oral booster after a subcutaneously 19 
injected prime. The pH of the stomach of C57Bl/6 mice was measured to be < 4.7 and it 20 
ranged from pH 5.8-7.1 in the small intestine, where the residence time of microcontainers 21 
was less than one hour. Eudragit® L100-55 was therefore chosen as lid material on the 22 
microcontainers as it remained stable in vitro at pH 4.7 and allowed release of the cubosomes 23 
within 30-60 min at pH 6.6, which simulated the mean pH of the distal half of the small 24 
intestine. In vitro small angle x-ray scattering showed that cubosomes dissolved in small 25 
intestinal fluid when not confined in microcontainers but when loaded into microcontainers 26 
they were released as hexosomes. However, while microcontainers could protect and release 27 
particles with OVA and Quil-A within relevant time frames in vitro, an immune response was 28 
not elicited in vivo after oral administration. Nonetheless, some effect was observed when the 29 
microcontainers were used to deliver oral boosters following a subcutaneous prime. This 30 
work indicates that oral vaccination with subunit vaccines has potential when combined with 31 
a parenteral prime and that oral delivery systems like microcontainers may be used to 32 
increase the potency of vaccines with low oral immunogenicity. 33 
 34 
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1. Introduction 40 
Most vaccines are administered by injection, demanding trained health care personnel to 41 
administer the vaccine [1]. This can limit distribution of vaccines due to costs and logistics. 42 
The problem is exacerbated by the need for most vaccines to be injected 2-3 times over 43 
several months in order to stimulate protective immunity [2]. For example, it is recommended 44 
that the diphtheria-tetanus-pertussis vaccine is given three times, yet 14 % of the world’s 45 
children did not receive the third immunization in 2016 [3].  46 
 47 
Self-administrable vaccines hold promise to greatly improve global vaccination coverage 48 
by simplifying logistics and eliminating the need for repeated health-care visits. The most 49 
attractive route for this is oral administration [1,4] with, for example, vaccine provided in a 50 
capsule. Capsules for oral administration could be easily distributed for patients to self-51 
medicate according to a provided schedule. This additionally eliminates the need for needles, 52 
which are reported to be the main risk associated with vaccination in developing countries 53 
due to improper usage [5]. Furthermore, oral vaccination has the advantage over parenteral 54 
vaccination that it offers the possibility to achieve mucosal immunity in the gastrointestinal 55 
(GI) tract as well as at distant mucosal compartments [6–8]. Zhu et al. reported on a large 56 
intestine targeted oral vaccine against HIV which gave protection against rectal and vaginal 57 
HIV challenge [9]. This indicated that mucosal immunization may be able to give protection 58 
against some targets that have proven elusive to effective immunization through parenteral 59 
immunization. 60 
 61 
Oral vaccines in routine clinical use are all against enteric pathogens. All are whole 62 
pathogen vaccines with most being live attenuated and only cholera vaccines being an 63 
inactivated vaccine [4,10]. All of them are very potent and live attenuated intestinal 64 
pathogens additionally have their own mechanisms of mucosal entry [10]. However, concerns 65 
over safety have caused an emphasis in modern vaccine research on developing subunit 66 
vaccines, which are based on purified antigenic fragments of pathogens [1,11]. This greatly 67 
improves the safety of the vaccine, but results in reduced immunogenicity, which is why 68 
adjuvants must be co-delivered with these antigens [1,4]. Subunit vaccines often use proteins 69 
or peptides as antigens, which are easily damaged and degraded by chemical and enzymatic 70 
challenges in the GI tract [4,11]. It is therefore important to design oral delivery systems that 71 
can protect the vaccines from these challenges. The ideal oral vaccine delivery system for 72 
subunit vaccines should protect the vaccine from degradation, limit the elimination/dilution 73 
of the vaccine in the GI tract, and facilitate uptake by M-cells in the intestine and by antigen 74 
presenting cells (APCs) to stimulate a strong immune response [10].  75 
 76 
Microcontainers are a new approach to enable oral vaccination with subunit vaccines. 77 
Microcontainers are reservoir-based cylindrical polymeric microstructures fabricated from 78 
the polymer SU-8 with precisely controllable dimensions and an opening at one end of the 79 
cylinder. They are a versatile delivery system that can be loaded with most powder 80 
formulations [12] as well as other types of formulations [13–15]. After loading, 81 
microcontainers can be sealed with a lid suitable for the application [16]. The use of pH-82 
sensitive lids gives them the potential for targeted delivery to specific segments of the GI 83 
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tract [13,14,17]. Microcontainers have been observed to be trapped in the intestinal mucus 84 
after intestinal perfusion in rats, thus aiding mucus penetration of the cargo [13]. They have 85 
furthermore been shown to be a promising oral drug delivery system [13,14,18,19], but have 86 
never been tested as an oral vaccine delivery system. Vaccine studies are normally performed 87 
in mice which do not have the same pH levels in the GI tract as rats [20]. New 88 
microcontainer lids suitable for use in mice are therefore developed in this study. The pH in 89 
both the stomach and small intestine of C57Bl/6 mice has not previously been studied, 90 
although the pH of the ileum and cecum of female C57Bl/6 mice has been reported to be 6.7 91 
and 6.4 respectively [21]. Other studies describe variable values from different strains as well 92 
as variation caused by external inputs (e.g. fasting) [20,22,23]. Since knowledge of the pH in 93 
the stomach and small intestine is crucial for pH controlled vaccine delivery, the pH in male 94 
C57Bl/6 was measured prior to this study (supplementary material). 95 
 96 
Quil-A is an adjuvant that is well tolerated orally [24,25], but needs to be coupled with a 97 
nanoparticle system such as cubosomes to be effective [26]. Cubosomes are composed of a 98 
highly twisted and ordered continuous lipid bilayer that forms two sets of intertwined and 99 
highly tortuous, but nonintersecting, water-channels. This gives cubosomes a large surface 100 
area making them flexible regarding the antigens and adjuvants they can carry [27]. Quil-A 101 
has previously been used for oral vaccination in a water/oil/water emulsion [28] and in 102 
ISCOMs [29–35] with some success indicating that Quil-A is suitable for oral use. We have 103 
previously reported the spray drying of cubosome precursors with ovalbumin (OVA) as 104 
model antigen and Quil-A as adjuvant. The powder formulation retained antigen integrity 105 
during storage at room temperature for at least 6 months and formed cubosomes after 106 
rehydration. The cubosomes elicited strong humoral and cellular immune responses after 107 
subcutaneous (s.c.) administration, but had no effect after oral administration indicating that a 108 
better oral delivery system was required [26]. These spray dried cubosomes are well suited 109 
for testing the efficacy of the microcontainers since they 1) have a high antigen content 2) 110 
appear to be stable during storage at room temperature and 3) are ineffective orally without a 111 
delivery system, although they are made with an adjuvant known to work mucosally. The aim 112 
of this study was to design microcontainers as oral delivery system for spray dried 113 
cubosomes, characterize the system in vitro and evaluate it in vivo in C57Bl/6 mice.  114 
 115 
2. Materials and Methods 116 
2.1.  Materials 117 
Dimodan® MO 90/D (monoolein) was kindly donated by Danisco (Grindsted, Denmark). 118 
Dextran (from Leuconostoc spp., 40 kDa), ovalbumin (Grade VII, from chicken egg white) 119 
and dibutyl sebacate were purchased from Sigma-Aldrich (St. Louis, MO, USA). Quil-A was 120 
obtained from Brenntag Biosector (Frederikssund, Denmark), phosphate buffered saline 121 
(PBS) tablets were acquired from Oxoid limited (Basingstoke, England) and Eudragit® L100-122 
55 (EL100-55) was purchased from Evonik (Darmstadt, Germany). 5,6-Carboxyfluorescein 123 
diacetate succinimidyl ester (CFSE) and CellTraceTM Violet Cell Proliferation Kit (CTV) 124 
were purchased from Molecular Probes® (Eugene, OR, USA). OVA257–264 peptide 125 
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(SIINFEKL) was acquired from Mimotopes (Clayton, Australia). PeCy7 anti-CD8, 126 
propidium iodide and HRP Goat anti-mouse IgG were from BioLegend® and APC-H7 anti-127 
CD4, PE anti-Vα2, biotin anti-Vβ5 and APC streptavidin from BD Pharmingen
TM. Complete 128 
mini protease inhibitor cocktail tablets were purchased from Roche Diagnostics (Mannheim 129 
Germany) and Mouse Anti-OVA IgA Antibody Assay Kits from Chondrex inc. (WA, USA). 130 
All other chemicals were of analytical grade and used as received. Milli-Q water (Merck 131 
Millipore, Darmstadt, Germany) was used throughout the study. 132 
 133 
2.2.  Mice 134 
6-8 weeks old male specific pathogen free C57BL/6 mice and male OT-I and OT-II mice 135 
were obtained from the HTRU, University of Otago, Dunedin, New Zealand. Mice had free 136 
access to food and water at all times. All experiments were approved by the Animal Ethics 137 
Committee at the University of Otago (AEC no. 80-16). 138 
2.3.  Spray drying cubosomes 139 
Cubosomes were prepared as previously described [26]. Briefly, Dimodan in ethanol (5.33 140 
mg/mL) was mixed 1:3.04 (v/v) with an aqueous solution of dextran, OVA and Quil-A (2.63, 141 
0.52 and 0.035 mg/mL, respectively). The mixture was spray dried on a Büchi B-290 mini 142 
spray dryer (Büchi Labortechnik AG, Flawil, Switzerland) with a pressure nozzle of 1.5 mm 143 
diameter. A feed rate of 4.5 mL/min was used with atomizing airflow rate of 667 L/h, inlet 144 
temperature of 150oC and 100 % aspirator rate. Particles without OVA were produced in the 145 
same way to be used as controls. Collected powders were stored at 86oC for 24 h and then 146 
dried at room temperature until use. 147 
2.4. Fabrication, loading and sealing of microcontainers 148 
Microcontainers were fabricated with the negative epoxy photoresist SU-8 by a two-step 149 
photolithography process as described previously [36]. However, in this study, the design 150 
was modified to achieve a larger internal diameter while preserving the external geometry of 151 
the microcontainers to increase the loading capacity. The microcontainers were produced on 152 
top of a fluorocarbon coated silicon wafer to allow easy mechanical removal from the wafer. 153 
The wafer was then cut into 12.8 by 12.8 mm2 chips containing 25 by 25 arrays of 154 
microcontainers using a dicing saw (DISCO, Kirchheim bei München, Germany). 155 
Microcontainers on chips were loaded with cubosome precursor powder using an embossing 156 
method as described previously [12]. A screen-mask was used to cover the gaps between the 157 
microcontainers thus filling the microcontainers without filling the space between them with 158 
powder. The average powder load in the microcontainers was estimated by weighing 21 sets 159 
of three individual microcontainers before and after loading.  160 
After loading, the microcontainers were sealed with the pH-sensitive polymer Eudragit® 161 
L100-55 (EL100-55) through a spray coating process. Isopropanol containing 1 % (v/v) 162 
EL100-55 and 5 % dibutyl sebacate (w/w in relation to EL100-55) was sprayed over the chip 163 
with microcontainers using an ExactaCoat spray coater (Sono Tek, Milton, NY, USA) 164 
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equipped with an ultrasonic nozzle actuated at 120 kHz (Accumist, Sono Tek, Milton, NY, 165 
USA). Spray coating parameters were as follows: feed flow rate 0.1 mL/min with generator 166 
power of 2.2 W and nebulizing air pressure of 0.02 kPa. The chips were kept at 40oC. The 167 
nozzle was positioned with a nozzle-to-microcontainer distance of 6.5 cm and moved 168 
laterally across the chip by a software controlled pattern to cover the entire chip equally. The 169 
translational speed of the nozzle was 5 mm/s and the coating was repeated to give a total of 170 
36 passages.  171 
2.5.  Microcontainer characterization and qualitative release study 172 
Microcontainers were visualized empty, loaded with cubosome precursor powder, and sealed 173 
with EL100-55 lids using a table top scanning electron microscope (SEM) (Hitachi 174 
TM3030plus, Tokyo, Japan). Samples were placed on carbon tape on metallic holders prior to 175 
investigation and then imaged using 15 kV acceleration voltage at 60x or 120x magnification. 176 
The thickness of the EL100-55 lids was estimated by covering half of an SU-8 coated chip 177 
and then spray coating it as described earlier on four independent samples. The height of the 178 
produced half-lids was measured by contact profilometry (Alpha-Step IQ Stylus profilometer, 179 
KLA-Tencor Corporation, Milpitas, USA) and used as estimate of the thickness of the lids 180 
deposited on the microcontainers. Profilometry was performed at a scan speed of 20 µm/s, 181 
using a 15.6 mg tip force at a sampling rate of 50 Hz. 182 
Release of cubosomes from microcontainers sealed with EL100-55 lids was investigated 183 
qualitatively with SEM. Three full chips of microcontainers were submerged in buffer 184 
simulating the pH of the mouse stomach (2 mM maleic acid at pH 4.7 and 37oC in a water 185 
bath rotating at 120 rpm) for 60 min. One chip was then removed from the buffer and imaged 186 
using SEM as described above while the two other chips were moved into buffer simulating 187 
intestinal pH (10 mM maleic acid at pH 6.6 and 37oC in a water bath rotating at 120 rpm) for 188 
30 or 60 min. The buffer was changed every 15 min to simulate the sink conditions of the 189 
intestine. The microcontainers were imaged by SEM and evaluated visually for the removal 190 
of lids and powder.  191 
Another in vitro release experiment was performed using gastric and intestinal fluids as 192 
release buffer. Here, individual microcontainers were submerged either into pooled gastric or 193 
pooled intestinal fluids (collected as described above) and placed for 30 min at 37oC in a 194 
water bath rotating at 120 rpm. Microcontainers were then recovered and imaged with SEM. 195 
The gastric and intestinal fluid was not washed off before imaging to avoid affecting the 196 
release with a washing step. 197 
2.6.  Small angle x-ray scattering of hydrated particles and particles released from 198 
microcontainers 199 
The internal structure of particles was investigated using small angle x-ray scattering (SAXS) 200 
at the Austrian SAXS/WAXS beamline at the synchrotron light source ELETTRA (Trieste, 201 
Italy). The x-ray beam had an energy of 8 keV (1.54 Å) and the samples were placed 1327 202 
mm from the detector. Diffraction patterns were converted to intensity vs. q-value plots to 203 
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identify relative peak positions for determination of the space group of the dominant internal 204 
structure of the samples. 205 
Powder precursors of cubosomes with OVA and Quil-A were suspended in vitro at 206 
approximately 50 mg/mL into stomach or intestinal fluids at 37oC. The structure of the 207 
particles was measured at 3 minute intervals with SAXS within timeframes ranging between 208 
6 and 18 min depending on the sample.  209 
Microcontainers were loaded with powder precursors of cubosomes with OVA and Quil-A 210 
and were submerged in PBS (9.5 mM, pH 7.3) for SAXS measurements at 3 min intervals 211 
over 39 min. Powder-filled microcontainers were then sealed with EL100-55 lids and 212 
submerged in PBS or in pooled intestinal fluid at 37oC. SAXS patterns were measured every 213 
3 min for 138 min (PBS) and 21 min (intestinal fluid).  214 
2.7.  Kinetics of microcontainer transit in the mouse GI tract 215 
Microcontainers filled with powder precursors of cubosomes with OVA and Quil-A and 216 
sealed with EL100-55 lids were filled into oral capsules designed for use in mice (gelatin 217 
capsules size M, Torpac®, USA). The average weight of a microcontainer was estimated by 218 
weighing sets of loaded and coated microcontainers. Each capsule was weighed before and 219 
after filling with microcontainers to estimate the number of microcontainers in each capsule. 220 
Mice were dosed with one capsule and sacrificed by cervical dislocation after 60 or 90 min 221 
followed by collection of their stomach, small intestine, cecum and colon. The small intestine 222 
was divided into a proximal and a distal segment. Segments were examined with optical 223 
microscopy (Olympus IX53 inverted microscope with 4x bright-field optics) to count the 224 
number of microcontainers present in each segment. For each mouse, the recovered numbers 225 
of microcontainers in each segment were normalized to the total number of microcontainers 226 
recovered from all segments. Three mice were used for each time point. 227 
2.8.  In vivo immunological investigation of microcontainers loaded with cubosomes as 228 
oral vaccines  229 
Two vaccine studies were performed. In both studies, 200 µL PBS with 2 x 106 naïve OT-I 230 
and OT-II lymphocytes (which have T cell receptors for CD8 and CD4 epitopes from OVA 231 
[37]) were injected intravenously (i.v.) into the tail vein 1-3 days prior to the first vaccination.  232 
The first study evaluated microcontainers as an oral vaccine. Six groups of five mice were 233 
given three oral immunizations as described in Figure 1a. Further details of the vaccination 234 
regime are included in Table S1. As a positive control, one group of mice was vaccinated 235 
twice s.c. with cubosomes containing 10 µg OVA and 0.67 µg Quil-A, while the oral 236 
vaccines contained 100 µg OVA and 6.7 µg Quil-A.  237 
The second study investigated microcontainers as an oral boost. Five groups of six mice 238 
received an s.c. prime followed by two boosts orally or s.c. as described in Figure 1b. Further 239 
details of the vaccination regime are included in Table S2. Doses were 10 µg OVA and 0.67 240 
µg Quil-A. 241 
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The s.c. vaccines were injected into the flank of the mice, whilst liquid oral vaccines were 242 
administered by gavage using a soft gavage needle (category #7202K, Fuchigami, Kyoto, 243 
Japan) and oral capsules were dispensed into the back of the mouth of the mouse using a 244 
dosing syringe. Four days after the last vaccination, mice were injected i.v. with 4 x 106 245 
C57Bl/6 lymphocytes pulsed with 10 µg/ml SIINFEKL and labelled with CFSE together with 246 
4 x 106 unpulsed lymphocytes stained with CTV. On day 33, mice were moved to fresh cages 247 
for collection of fresh fecal pellets from the cage floors on day 34. Fecal pellets were stored 248 
at -20oC until analysis. Mice were sacrificed on day 34 and blood, spleens and lymph nodes 249 
(mesenteric and inguinal lymph nodes from mice vaccinated orally or s.c., respectively) were 250 
collected. 251 
 252 
 253 
Figure 1. Schematics of the in vivo studies investigating (a) oral prime and boost or (b) s.c. 254 
prime followed by oral boosts. Positive control groups received s.c. prime and boost in both 255 
studies. Numbering of groups correspond with those of Tables S1 and S2. 256 
 257 
a) 
b) 
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2.9.  Flow cytometry 258 
Spleens and lymph nodes from individual mice were processed into single cell suspensions 259 
essentially as described previously [38]. Aliquots of cells were stained with anti-CD8, anti-260 
CD4, anti-Vα2 and anti-Vβ5 antibodies and the live/dead stain propidium iodide. Data was 261 
acquired on a BD FACSCantoTM II (BD Biosciences) and analyzed using FlowJo version 262 
10.3 (Tree Star, Inc.) with the gating strategy shown in Figure S1. Antigen specific killing of 263 
peptide pulsed target cells was evaluated as described previously [26]. 264 
2.10. Measurement of OVA-specific serum IgG and OVA-specific fecal and serum IgA 265 
Sera were separated from whole blood and OVA-specific serum IgG was measured by 266 
ELISA as previously described [26]. Briefly, wells were coated with OVA and then blocked 267 
with 2 % w/v BSA in PBS (9.5 mM, pH 7.3). Sera were diluted 1:100, serially diluted across 268 
well plates (high-binding 96 well plate, Corning inc. Corning, NY, USA) and incubated for 2 269 
h. 225 ng/mL HRP Goat anti-mouse IgG was used as detection antibody and color was 270 
developed using a substrate reagent pack (R&D SYSTEMS®, MN, USA). Color development 271 
was stopped with 2 M H2SO4 and absorbance at 450 nm was read using a Polarstar Omega 272 
Microplate Reader (BMG Labtech, Ortenberg, Germany) 273 
For IgA measurement, fecal pellets were powdered with morter and pestle and IgA was 274 
extracted from the solids by mixing at 150 mg/mL in PBS (9.5 mM, pH 7.3) containing 275 
protease inhibitors used according to the manufacturer’s protocol. The extraction was run for 276 
45 min and agitated repeatedly by aspirating and ejecting through a 1 mL syringe. Solids 277 
were separated from liquid by centrifugation for 10 min at 2,000 G and OVA-specific IgA in 278 
the supernatants was measured using an ELISA kit according to manufacturer’s instructions. 279 
OVA-specific IgA from pooled undiluted sera was measured using the same protocol. 280 
2.11. Statistics 281 
Data are presented as mean ± standard deviation (SD), except the pH measurements which 282 
are presented as median with quartiles and extrema together with the mean. Statistical 283 
analysis was performed by one-way ANOVA and Tukey’s multiple comparisons test using 284 
Prism 7 (GraphPad, San Diego, USA).  285 
 286 
3. Results and discussion 287 
3.1. Cubosomes retain their structure in stomach fluid but are degraded in intestinal fluid 288 
A dry flowable powder of cubosome precursors with OVA and Quil-A was prepared by spray 289 
drying and formed Pn3m cubosomes when dispersed in PBS as previously described [26]. 290 
Following oral administration, however, the gastric and intestinal fluids may affect the 291 
structure of the nanoparticles in vivo and this has not previously been investigated. To 292 
investigate if cubosomes form after oral administration to mice, the powder was mixed into 293 
stomach and intestinal fluids from mice in vitro. Cubosomes formed immediately in stomach 294 
fluid and remained intact for at least 18 min (Figure 2). Conversely, in intestinal fluid from 295 
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either intestinal segment, SAXS patterns without peaks (characteristic of vesicles) were 296 
obtained (Figure 2). This indicates that cubosomes are stable for at least 18 min in stomach 297 
fluid, but quickly lose their cubic structure to form vesicles in intestinal fluid.  298 
Since cubosomes are lipid-based particles, they may be expected to be emulsified into 299 
vesicles by bile salts. This is consistent with our results as bile salts are present in large 300 
amounts in the intestine while no or only small amounts of bile salts are reported to be 301 
present in the stomach [39]. For oral administration to mice, it was therefore important that 302 
the microcontainers are able to not only protect the antigen from chemical and enzymatic 303 
degradation in the stomach, but also to protect the cubosomes from emulsification by bile 304 
salts in the intestine. Because microcontainers are known to be trapped in the mucus close to 305 
the intestinal wall [13], emulsification would be reduced by the release of cubosomes near the 306 
epithelium. As will be shown below, the chemistry of the lid may also provide protection of 307 
the particles even after release. 308 
 309 
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Figure 2. q vs. intensity patterns obtained from SAXS measurements of cubosomes with 311 
OVA and Quil-A mixed in vitro with fluids from segments of the GI tract of mice at 37oC. 312 
Measurements were performed at 0 and 18 min after mixing cubosomes into stomach fluid 313 
and 0 min after mixing cubosomes into fluid from the proximal or distal half of the small 314 
intestine.  315 
 316 
3.2. Fabrication, loading and coating of microcontainers 317 
Microcontainers were fabricated with an outer diameter of 326.3 ± 1.0 µm and height of 318 
255.4 ± 6.0 µm, and with an inner diameter of 231.5 ± 0.9 µm and height of 216.8 ± 6.4 µm, 319 
giving a reservoir volume of 9.1 ± 0.3 nL (n = 4, mean ± SD). Microcontainers were loaded 320 
with 6.6 ± 4.6 µg/microcontainer of powder and then sealed with EL100-55 lids. The average 321 
thickness of the lid coating was measured by contact profilometry to be 29.7 ± 3.5 µm with a 322 
surface roughness (SD of the thickness of the individual chip) ≤ 1.2 µm. 323 
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 324 
3.3. Release of OVA and Quil-A cubosomes from microcontainers 325 
The pH-activated release of cubosomes from coated microcontainers was tested in vitro. For 326 
simulation of gastric pH, the highest pH that may be expected in the stomach was chosen to 327 
ensure that biological variance would not cause unexpected lid disintegration in the 328 
subsequent in vivo evaluation. Microcontainers (Figure 3a) were therefore submerged in 329 
buffer at pH 4.7 and 37oC to simulate stomach pH of C57Bl/6 mice (Supplementary 330 
material). After 60 min, the EL100-55 lids were completely intact (Figure 3b) and the 331 
microcontainers were moved to buffer at pH 6.6 to simulate the pH of the distal segment of 332 
the small intestine (Supplementary material). Here, the lids dissolved and most of the 333 
cubosomes were released within 30 min (Figure 3c), although a small amount was still left at 334 
the top of most microcontainers (but not deep into the reservoir). After 60 min, most 335 
microcontainers were empty (Figure 3d).  336 
The experiment was repeated in vitro using fluids from the stomach, and the proximal- and 337 
distal segments of the small intestines of mice. Once again, lids were intact after 30 min in 338 
the stomach, but dissolved within 30 min in the proximal segment of the intestine (Figure 339 
S2). The microcontainers generally appeared empty after 30 min in fluid from either segment 340 
of the intestine but the degree of emptying was difficult to evaluate due to the presence of 341 
sticky solids in the intestinal fluids (Figure S2). Lids made from Eudragit L100-55 thus 342 
appear to have the same function in mice as we have previously observed for rats with lids 343 
made from Eudragit L100 [13]. 344 
 345 
Figure 3. SEM images showing dry microcontainers on a chip after loading with cubosomes 346 
and coating with EL100-55 (a). Microcontainers were soaked for 60 min in 2 mM maleic acid 347 
at pH 4.7 simulating the pH of the mouse stomach (b) and then in 10 mM maleic acid at pH 348 
6.6 simulating pH of the mouse intestine for 30 min (c) and 60 min (d). 349 
 350 
3.4. Effect of microcontainers on particle morphology 351 
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The entrapment of monoolein-based cubosome precursors in microcontainers sealed with 352 
Eudragit® S100 lids has previously been reported to result in hexosomes being formed after 353 
release of the precursors into water [17]. However, it was not tested whether it was the 354 
microcontainers or the lids that cause the change in particle morphology. Here, the effect on 355 
particle morphology of sealing the microcontainers with EL100-55 lids was investigated in 356 
addition to the effect of microcontainers on their own. Powder precursors loaded into 357 
microcontainers and released into PBS were investigated with SAXS. Release of cubosome 358 
precursors from microcontainers without lids resulted in Bragg peaks at relative positions of 359 
√2: √3: √4: √6: √8: √9 (Figure 4a) characteristic of Pn3m cubic phase [40,41] similar to 360 
those from cubosomes without microcontainers [26]. The peaks were evident after 6 min and 361 
persisted thereafter (shown at 30 min, the measurement was stopped after 39 min). This 362 
indicates that microcontainers do not affect particle morphology, as was expected since the 363 
cubosomes only form after rehydration [26] and thus after release. 364 
Particles released from microcontainers with EL100-55 lids resulted in Bragg peaks at 365 
relative positions of √1: √3: √4  (Figure 4a) characteristic of hexagonal phase [40]. SAXS 366 
patterns from the hexosomes became increasingly sharper even 60 min after submersion in 367 
PBS. Since microcontainers do not affect particle morphology, this indicates that after 368 
dissolution of the lids, the components of the lids interact with the lipid changing the particle 369 
morphology from cubosomes to hexosomes.  370 
In the pure monoolein/water phase diagram, the hexagonal phase exists only at temperatures 371 
above 80oC [42]. However, the addition of other amphiphiles with a higher hydrophobicity 372 
than monoolein, or lipophilic additives, can transform the cubic phase to a hexagonal phase 373 
[42,43]. At pH 6.6, EL100-55 will be mostly deprotonated and thus have a hydrophilic 374 
structure that allows its dissolution in water. The addition of EL100-55 at pH 6.6 is therefore 375 
not an obvious driving factor for the observed phase change. The only other component of the 376 
lid is the dibutyl sebacate used as plasticizer for the EL100-55 lids. Dibutyl sebacate was 377 
chosen for its hydrophobic nature, which provides more water tight lids than when using a 378 
hydrophilic alternative [44]. It is therefore likely to become incorporated into the monoolein 379 
bilayers where it might affect the packing of the lipids increasing curvature and consequently 380 
driving the phase change from the inverse cubic to the inverse hexagonal structure [45,46]. 381 
However, no plasticizer was used in the study by Nielsen et al., where a mixture of 382 
cubosomes and hexosomes were released from Eudragit® S100 coated microcontainers [17]. 383 
Since the two Eudragit types are copolymers composed of the same monomers at different 384 
ratios, it is likely that both EL100-55 and dibutyl sebacate have influence on the observed 385 
complete phase change observed in this study. The explanation might be that their 386 
incorporation reduces the packing frustration of the lipid bilayer inherent to the hexagonal 387 
structure [46]. 388 
Interestingly, hexosomes were also formed when the precursor powder was released from 389 
microcontainers with lids into intestinal fluid from mice (Figure 4b). They take some time to 390 
form the crystal structure though as evident from the time-dependent change of diffraction 391 
pattern from a soft hump to clear peaks. Since release of cubosomes from the microcontainers 392 
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is expected to happen in the mucus, it is likely that hexosomes with OVA and Quil-A will 393 
form in vivo in the mucus in close proximity to the intestinal wall, where the antigen-394 
sampling M-cells and dendritic cells are present. Any type of particle generally facilitates the 395 
recognition and uptake of antigen by antigen presenting cells [47]. This morphology change 396 
is therefore likely not of substantial importance to the stimulation of an immune response. 397 
However, release of actives from the bulk hexagonal phase is generally slower than from the 398 
bulk cubic phase [48]. It could therefore be speculated that hexosomes retain the antigen 399 
better than cubosomes, and thereby might stimulate a better immune response [11]. 400 
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Figure 4. q vs. intensity patterns obtained from SAXS measurements of particles with OVA 402 
and Quil-A released from microcontainers at (a) 37oC in PBS and (b) in mouse intestinal 403 
fluid. SAXS patterns shown in (a) are from particles released from microcontainers without 404 
lid after 30 min and with lid after 30, 60 and 138 min. SAXS patterns shown in (b) are from 405 
particles released from microcontainers with lid just after submersion in mouse intestinal 406 
fluid and after 21 min. 407 
3.5. Kinetics of microcontainer transit in the mouse GI tract 408 
The transit time of microcontainers or similarly sized particles through the GI tract of mice 409 
has never been evaluated, but is important for interpretation of in vitro studies of vaccine 410 
release from the microcontainers. To investigate whether the microcontainers stay long 411 
enough in the intestine to allow release of the vaccine before the microcontainers are expelled 412 
with the feces, the transit time through the GI tract was evaluated. Mice were administered 413 
one capsule loaded with microcontainers and were sacrificed after 60 or 90 min. 414 
Microcontainers were quantified by microscopy and 86 ± 11 % of the estimated number of 415 
administered microcontainers were found in each mouse (Figure 5). The microcontainers 416 
were generally spread widely within each mouse indicating a large variability in how fast 417 
individual microcontainers move through the GI tract. However, after 60 minutes more than 418 
60 % of the microcontainers had passed the stomach, and 58 % of the microcontainers were 419 
distributed along the small intestine. After 90 min, the majority of microcontainers recovered 420 
were present in the cecum and colon. The time available for release in the small intestine is 421 
therefore short and some of the vaccine might be released in the large intestine. Both the 422 
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cecum and the colon contain lymphoid tissue [20] and are good mucosal vaccine targets to 423 
obtain immunity at rectal and vaginal mucus surfaces [9].  424 
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Figure 5. Relative numbers of recovered microcontainers found in the stomach, proximal-427 
and distal half of the small intestine, cecum and colon in mice killed 60 or 90 min after oral 428 
administration. Error bars represent mean ± SD (n = 3).  429 
 430 
3.6. Oral cubosomes elicit a weak humoral immune response but no response when 431 
delivered in microcontainers 432 
Microcontainers appear to have promise as an oral delivery system and were therefore 433 
evaluated in vivo. Microcontainers were administered in capsules because their pH-sensitive 434 
lids would dissolve in buffer at neutral pH. OVA-specific serum IgG titers were measured by 435 
ELISA to evaluate the humoral immune response to the vaccines. A strong anti-OVA IgG 436 
response was seen after s.c. administration as previously reported [26]. Oral cubosomes 437 
resulted in slightly increased IgG response in one experiment (Figure 6), but not in the 438 
replicate of the experiment (not shown). OVA and Quil-A delivered in capsules or in 439 
microcontainers (in capsules) with or without cubosomes had no effect.  440 
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Figure 6. OVA-specific serum IgG antibody titers. Mice were given vaccines three times 442 
orally or two times s.c. as indicated with 14 days between each vaccination. Data shown are 443 
from individual mice plus the average and SD (data is from 1 of 2 independent experiments, 444 
n = 4-5 mice/experiment). * p < 0.5, ** p < 0.1, *** p < 0.001, cubo = cubosomes, MC = 445 
microcontainers. 446 
 447 
Fecal and serum OVA-specific IgA titers were measured by ELISA to evaluate the mucosal 448 
immune response. Low and inconsistent levels of IgA were seen in pooled fecal and serum 449 
samples from oral cubosomes (Figure 7). Mice treated orally with cubosomes in 450 
microcontainers had low levels of IgA in serum in one experiment.  451 
 452 
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 453 
Figure 7. OVA-specific IgA from (a) fecal samples collected at the time of sacrifice and (b) 454 
serum samples. Mice were given vaccines three times orally or two times s.c. as indicated 455 
with 14 days between each vaccination. Data are from pooled mice with 4-5 mice/group. 456 
cubo = cubosomes, MC = microcontainers. 457 
 458 
3.7. Oral cubosomes inconsistently elicit a cellular immune response but no response 459 
when delivered in microcontainers 460 
Expansion of OVA-specific transgenic cells was used to evaluate the cellular immune 461 
response to the vaccines (Figure 8) along with an in vivo cytotoxicity assay to measure 462 
cytotoxic T cell responses (Figure 9). For the in vivo cytotoxicity assay, killing of OVA-463 
peptide labelled lymphocytes injected i.v. two days before sacrifice was measured.  464 
Subcutaneous injection of cubosomes elicited strong OVA-specific CD8+ expansion in lymph 465 
nodes and spleens (Figure 8a and c) as well as target cell killing (Figure 9) as observed 466 
previously [26]. Oral cubosomes with OVA and Quil-A were able to elicit a strong CD8+ 467 
response in two mice, but had no effect in the remaining three mice (Figure 8a and c). All 468 
other oral treatments had no effect. The CD4+ responses were generally weak (Figure 8b and 469 
d). A slight CD4+ response was observed in the same mice treated with oral cubosomes with 470 
OVA and Quil-A that also expressed strong CD8+ responses and in some of the mice treated 471 
with cubosomes s.c. Oral cubosomes caused variable target cell killing, but this was not 472 
comparable to the effect of s.c. cubosomes (Figure 9). All other oral groups did not stimulate 473 
target cell killing.  474 
We have previously observed that these cubosomes do not work orally when administered in 475 
powder form in a capsule [26]. In this study, the powder form of the cubosomes in 476 
microcontainers was also ineffective, whereas cubosomes that had been rehydrated prior to 477 
gavage had a small effect. It therefore seems that when this vaccine is administered in powder 478 
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form, it is not suitable for oral delivery, even if using an oral delivery system. However, both 479 
cubosomes and microcontainers have the potential to be further developed and 480 
micro481 
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 521 
Figure 9. In vivo killing of adoptively transferred OVA-peptide labelled T cells in spleens. 522 
Mice were given vaccines three times orally or two times s.c. as indicated with 14 days 523 
between each vaccination. Data shown are results from individual mice together with mean 524 
and SD from one of two independent experiments (n = 4-5 mice/experiment). ***p < 0.001, 525 
cubo = cubosomes, MC = microcontainers. 526 
 527 
3.8. Oral cubosomes in microcontainers have some effect as booster vaccine 528 
Doherty et al. reported that after an s.c. injected prime, an oral boost could stimulate a similar 529 
level of protective immunity as a s.c. boost, although the oral vaccine was unable to prime an 530 
immune response [49]. We therefore investigated if microcontainers with cubosomes with 531 
OVA and Quil-A could stimulate an immune response when used as oral boost after an s.c. 532 
injected prime of cubosomes.  533 
Mice were given s.c. primes followed by two oral boosts (or s.c. boosts for the positive 534 
control). In this experiment, the oral dose was reduced ten times to be the same as the s.c. 535 
dose (10 µg OVA and 0.67 µg Quil-A). OVA-specific serum IgG titers stimulated by s.c. 536 
cubosomes was stronger than all oral groups (p < 0.001, Figure 10). Nonetheless, oral 537 
boosters of cubosomes in microcontainers gave a slightly better antibody response than oral 538 
boosters of cubosomes without microcontainers, indicating that the microcontainers help 539 
deliver cubosomes orally as a booster vaccine (not significant, Figure 10). However, this 540 
effect was not seen in the cellular response where CD8+ expansion after oral treatment with 541 
cubosomes in microcontainers was similar to the CD8+ expansion after oral treatment with 542 
cubosomes without microcontainers (Figure 11). The results could indicate that a parenteral 543 
primer is necessary in later studies. 544 
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Figure 10. OVA-specific serum IgG antibody titers. Mice were given a priming dose of 546 
vaccine by s.c. injection and then two s.c. or oral boosters as indicated. Vaccines were given 547 
at 14 day intervals. In groups that received oral boosters with microcontainers, the s.c. prime 548 
was injected without microcontainers. Data shown are from individual mice from a 549 
representative experiment of three independent experiments together with mean and SD (n = 550 
5-6 mice/experiment). cubo = cubosomes, MC = microcontainers. 551 
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Figure 11. In vivo expansion of OVA-specific CD8+ cells in spleens. Mice were given a 554 
priming dose of vaccine by s.c. injection and then two s.c. or oral boosters as indicated. 555 
Vaccines were given at 14 day intervals. In groups that received oral boosters with 556 
microcontainers, the s.c. prime was injected without microcontainers. Data shown are from 557 
individual mice from a representative experiment of three independent experiments as well as 558 
their average and SD (n = 5-6 mice/experiment). cubo = cubosomes, MC = microcontainers. 559 
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 560 
4. Conclusion 561 
Microcontainers hold great promise for protection of their cargo through the GI tract until 562 
release in the mucus of the small intestine. The transit time of microcontainers through the 563 
small intestine of mice is approximately 30-60 min. After release of the vaccine in the 564 
intestine, these lids caused a change of the particle morphology from cubosomes to 565 
hexosomes, which were stable for at least 21 min in intestinal fluid. However, 566 
microcontainers were not successful in allowing oral delivery of a vaccine consisting of 567 
cubosomes with OVA and Quil-A, but were able to slightly improve the humoral response to 568 
oral boosters using the same vaccine at low doses. This work indicates that an oral delivery 569 
system such as microcontainers should be focused on increasing the potency of vaccines that 570 
have some immunogenicity after oral administration. This study further indicates that oral 571 
vaccination is more easily achieved for booster vaccines after an injected primer. 572 
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Supplementary information 755 
 756 
Table S1: Vaccinations in study 1, where microcontainers were tested as an oral vaccine 757 
system. 758 
Group no. Vaccine formulation? Dosage form Administrated 
on days 
1 Microcontainers + cubosomes + 
OVA + Quil-A 
Oral capsule 0, 14 and 28 
2 Microcontainers + OVA + Quil-A Oral capsule 0, 14 and 28 
3 Cubosomes + OVA + Quil-A In 100 µL PBS orally 0, 14 and 28 
4 OVA + Quil-A Oral capsule 0, 14 and 28 
5 Microcontainers + cubosomes + 
Quil-A 
Oral capsule 0, 14 and 28 
6 Cubosomes with OVA and Quil-A In 200 µL PBS s.c. 14 and 28 
 759 
 760 
Table S2: Vaccinations in study 2 where microcontainers were tested as an oral booster 761 
vaccine system. 762 
Group no. Primer (day 0) Booster (day 14 and 28) 
1 Cubosome + OVA + Quil-A in 200 
µL PBS s.c. 
Microcontainers + cubosomes + OVA 
+ Quil-A in oral capsule 
2 Cubosome + OVA + Quil-A in 200 
µL PBS s.c. 
Cubosomes + OVA + Quil-A orally in 
100 µL PBS 
3 OVA + Quil-A in 200 µL PBS s.c. OVA + Quil-A orally in 100 µL PBS 
4 Cubosome + Quil-A in 200 µL PBS 
s.c. 
Microcontainers + cubosomes + Quil-
A in oral capsule 
5 Cubosome + OVA + Quil-A in 200 
µL PBS s.c. 
Cubosome + OVA + Quil-A in 200 µL 
PBS s.c. 
 763 
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 764 
Figure S1. Gating setup for FACS analysis of OVA-peptide labelled target cells and 765 
transgenic OVA-specific CD4+ and CD8+ expansion. The example shown is from splenocytes 766 
from a mouse receiving oral PBS with cubosomes with OVA and Quil-A. Single cells were 767 
selected (a), followed by selecting lymphocytes (b), and excluding dead cells (c). OVA-768 
peptide pulsed and un-pulsed target cells were selected for the in vivo cytotoxic T cell killing 769 
assay and native cells selected for the OVA-specific T cell expansion assay (d). Gates were 770 
then set to select native cells expressing CD4+ and CD8+ receptors (e), and then transgenic 771 
vα2
+ and vβ5
+ receptors on CD4+ cells (f), and CD8+ cells (g). 772 
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 773 
pH of the GI-tract of mice 774 
Methods 775 
Mice were sacrificed and their stomach and small intestine collected. The small intestine was 776 
divided into two segments (proximal and distal) of equal length. Segment fluid from four 777 
mice were pooled to allow complete submersion of a pH-microelectrode (Metrohm, Herisau, 778 
Switzerland) connected to a SensION+ pH31 pH meter (HACH®). Immediately after 779 
collecting the gastric and intestinal fluids, pH measurements were performed at 37oC on five 780 
independent samples. 781 
Results 782 
The pH of the fluid from the stomach and the proximal- and distal half of the small intestine 783 
was measured immediately after sacrificing the mice. The average pH in the stomach was 4.4 784 
and the highest individual pH-value recorded in the stomach was 4.7 (Figure S2). The 785 
average pH of the small intestine was 5.9 (proximal segment) and 6.6 (distal segment). The 786 
lowest individual pH-value recorded in the intestine was 5.8 and the highest 7.1. These 787 
results showed that the pH-sensitive polymer must be stable below pH 4.7 and must dissolve 788 
at pH-values above 5.8. EL100-55 was therefore chosen as it dissolves at pH-values above 789 
5.5.  790 
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Figure S2. pH of fluids from the GI tract from mice measured at 37oC immediately after 792 
sacrifice. Whiskers on the boxplots indicate maximum and minimum (n = 5). Averages are 793 
written above each group, and pH 5.5, above which EL100-55 begins to dissolve, is marked 794 
on the figure. 795 
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 797 
Figure S3. Representative SEM images of microcontainers after 30 min submersion into 798 
fluid from the stomach (a), proximal segment of the small intestine (b), and distal segment of 799 
the small intestine (c), in vitro at 37oC and rotation at 120 rpm. 800 
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